Art. -Nr.: HY-19356

Rocaglamide

(Synonyms: Roc-A)

31 Cited Publications

Kundenbewertung

Based on 31 publication(s) in Google Scholar

Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC₅₀ of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.76%
CAS. Nr.: 84573-16-0
Formel: C₂₉H₃₁NO₇
Molecular Weight:505.56

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Rocaglamide Chemical Structure

CAS. Nr.: 84573-16-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (31)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

eIF4	HSF1 50 nM (IC₅₀)

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle HSP Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.006 μg/mL Compound: 2	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 9214732]
HCT-8	IC₅₀	0.007 μg/mL Compound: 2	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 9214732]
HEK293	IC₅₀	2.6 μM Compound: Rocaglamide	Inhibition of TNF alpha-induced NF-kappaB (unknown origin) activation in HEK293 cells after 6 hrs by luciferase reporter gene assay Inhibition of TNF alpha-induced NF-kappaB (unknown origin) activation in HEK293 cells after 6 hrs by luciferase reporter gene assay	[PMID: 26863083]
HeLa	ED₅₀	2 μM Compound: rocaglamide	Inhibition of NF kappaB p50 subunit signaling pathway in human HeLa cells by biotinylated-ELISA Inhibition of NF kappaB p50 subunit signaling pathway in human HeLa cells by biotinylated-ELISA	[PMID: 19422206]
HeLa	IC₅₀	0.075 μM Compound: rocaglamide	Inhibition of NFkappa p50 isolated from nuclear extract of human HeLa cells assessed as blockade of binding to biotinylated consesus sequence by chemiluminescence assay Inhibition of NFkappa p50 isolated from nuclear extract of human HeLa cells assessed as blockade of binding to biotinylated consesus sequence by chemiluminescence assay	[PMID: 20384315]
HeLa	IC₅₀	0.075 μM Compound: Rocaglamide	Inhibition of NFkappa p65 in nuclear extract of human HeLa cells assessed as blockade of NFkappa p65 binding to biotinylated-consesus sequence by ELISA Inhibition of NFkappa p65 in nuclear extract of human HeLa cells assessed as blockade of NFkappa p65 binding to biotinylated-consesus sequence by ELISA	[PMID: 21428375]
HeLa	IC₅₀	0.075 μM Compound: Rocaglamide	Inhibition of NFkappa p65 isolated from nuclear extract of human HeLa cells by ELISA Inhibition of NFkappa p65 isolated from nuclear extract of human HeLa cells by ELISA	[PMID: 21513293]
HeLa	IC₅₀	0.1 μM Compound: 7; RocA	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by [35S] methionine incorporation assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by [35S] methionine incorporation assay	[PMID: 33592144]
HeLa	IC₅₀	0.12 μM Compound: Rocaglamide	Inhibition of TNF alpha stimulated NF-KappaB p65 in human HeLa nuclear extract assessed as decrease in NF-KappaB translocation to nucleus measured after 5 hrs by ELISA Inhibition of TNF alpha stimulated NF-KappaB p65 in human HeLa nuclear extract assessed as decrease in NF-KappaB translocation to nucleus measured after 5 hrs by ELISA	[PMID: 31120251]
HeLa	IC₅₀	4 μM Compound: rocaglamide	Inhibition of NFkappa p65 isolated from nuclear extract of human HeLa cells assessed as blockade of binding to biotinylated consesus sequence by chemiluminescence assay Inhibition of NFkappa p65 isolated from nuclear extract of human HeLa cells assessed as blockade of binding to biotinylated consesus sequence by chemiluminescence assay	[PMID: 20384315]
HepG2	CC₅₀	44.5 nM Compound: rac-1b	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 38127656]
HepG2	CC₅₀	549.5 nM Compound: rac-1b	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 38127656]
HT-29	ED₅₀	0.005 μM Compound: rocaglamide	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 23301897]
KB	IC₅₀	0.006 μg/mL Compound: 2	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 9214732]
MDA-MB-231	IC₅₀	135 nM Compound: (-)-2; (-)-Roc A	Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat CCGCCG in 5'- UTR containing luciferase reporter gene assay Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat CCGCCG in 5'- UTR containing luciferase reporter gene assay	[PMID: 32470302]
MDA-MB-231	IC₅₀	20 nM Compound: (-)-2; (-)-Roc A	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell proliferation incubated for 72 hrs by CellTiter-Glo reagent based assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell proliferation incubated for 72 hrs by CellTiter-Glo reagent based assay	[PMID: 32470302]
MDA-MB-231	IC₅₀	231 nM Compound: (-)-2; (-)-Roc A	Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat CAACAA in 5'- UTR containing luciferase reporter gene assay Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat CAACAA in 5'- UTR containing luciferase reporter gene assay	[PMID: 32470302]
MDA-MB-231	IC₅₀	4.7 nM Compound: (-)-2; (-)-Roc A	Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat AGAGAG in 5'- UTR containing luciferase reporter gene assay Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat AGAGAG in 5'- UTR containing luciferase reporter gene assay	[PMID: 32470302]
MDA-MB-231	IC₅₀	47 nM Compound: (-)-2; (-)-Roc A	Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat GGCGGC in 5'- UTR containing luciferase reporter gene assay Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat GGCGGC in 5'- UTR containing luciferase reporter gene assay	[PMID: 32470302]
NCI-H929	IC₅₀	3.9 μM Compound: Rocaglamide	Cytotoxicity against human NCI-H929 cells after 48 hrs by MTS assay Cytotoxicity against human NCI-H929 cells after 48 hrs by MTS assay	[PMID: 26863083]
P388	IC₅₀	0.005 μg/mL Compound: 2	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 9214732]
RPMI-7951	IC₅₀	0.002 μg/mL Compound: 2	Cytotoxicity against human RPMI7951 cells Cytotoxicity against human RPMI7951 cells	[PMID: 9214732]
TE-671	IC₅₀	0.006 μg/mL Compound: 2	Cytotoxicity against human TE671 cells Cytotoxicity against human TE671 cells	[PMID: 9214732]

In Vitro

Rocaglamide enhances TRAIL-induced apoptosis in resistant HCC cells. Treatment with Rocaglamide alone leads to apoptosis in 9% HepG2 and 11% Huh-7 cells and treatment with TRAIL induces apoptosis in 16% HepG2 and 17% Huh-7 cells. However, the combination of Rocaglamide and TRAIL induces apoptosis in 55% HepG2 and 57% Huh-7 cells, which is evidently more than an additive effect. A similar result is obtained by measurement of cell viability using crystal violet staining. Rocaglamide has the potential to sensitize highly chemoresistant HepG2 and Huh-7 cells to TRAIL-based therapy^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tumor volumes in the Rocaglamide-treated group are 45±12% compared with the control group. Rocaglamide significantly suppresses tumor growth compared with that in the control group. Treatment with Rocaglamide does not lead to any reduction in body weight and no apparent signs of toxicity are observed in the mice during the treatment, suggesting that Rocaglamide is generally tolerated well^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 84573-16-0
Appearance Solid
Molecular Weight 505.56
Formel C₂₉H₃₁NO₇
Color White to off-white
SMILES

O[C@]12[C@](OC3=CC(OC)=CC(OC)=C32)(C4=CC=C(C=C4)OC)[C@H](C5=CC=CC=C5)[C@H]([C@H]1O)C(N(C)C)=O
Synonyms

Roc-A
Structure Classification
- Alkaloids
- Other Alkaloids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (31)

All Bio/Physico-chemical AssayIPWB

Sort by:

Journal Impact Factor

Nat Commun

Reanalysis of ribosome profiling datasets reveals a function of rocaglamide A in perturbing the dynamics of translation elongation via eIF4A. [Abstract]

2023 Feb 2;14(1):553. PMID: 36725859

Rocaglamide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Feb 2;14(1):553. [Abstract]

Rocaglamide (RocA) (0.03-3 μM; 30 min) caused strong accumulation of ribosomes in both the upstream and downstream regions around the start codons in HEK293 cells in a dose-dependent manner.

Rocaglamide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Feb 2;14(1):553. [Abstract]

Rocaglamide (RocA) (0.03-3 μM; 30 min) induced dramatic accumulation of ribosomes in the CDS of the ERGs near the start codon in a dose-dependent manner, indicating stalling of early translation elongation.

Rocaglamide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Feb 2;14(1):553. [Abstract]

Rocaglamide (RocA) (3 μM; 30 min) greatly reduced the disome densities in the CDS regions of the IRGs and increased the disome densities in the first～50 codons of the ERGs.

Rocaglamide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Feb 2;14(1):553. [Abstract]

Rocaglamide (RocA) (0.03-3 μM; 30 min) resulted in significantly reduced firefly luciferase levels, in relative to the Renilla luciferase levels as references.

Rocaglamide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Feb 2;14(1):553. [Abstract]

Rocaglamide (RocA) (3 μM; 30 min) resulted in further increase of the binding affinity of eIF4A with the CDS-MS2bs sequences.
Nat Commun

Suppression of mitochondrial ROS by prohibitin drives glioblastoma progression and therapeutic resistance. [Abstract]

2021 Jun 17;12(1):3720. PMID: 34140524

Rocaglamide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 17;12(1):3720. [Abstract]

The expression of PRDX3 and stem cell markers is decreased upon rocaglamide A (RocA) treatment in a time-dependent and dose-dependent manner.
Autophagy

Salmonella Typhimurium persistently infects host via its effector SseJ-induced PHB2-mediated mitophagy. [Abstract]

2025 Jun;21(6):1228-1244. PMID: 39902787
Autophagy

PHB2 (prohibitin 2) promotes PINK1-PRKN/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis. [Abstract]

2020 Mar;16(3):419-434. PMID: 31177901
Sci Adv

Shifting IRES versus Cap-initiated translation during homeostatic stem cell differentiation and stress. [Abstract]

2026 May 22;12(21):eadz7896. PMID: 42172329
Proc Natl Acad Sci U S A

eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations. [Abstract]

2024 Oct 29;121(44):e2321305121. PMID: 39436655
Cell Rep

The impact of Coronavirus Nsp1 on host mRNA degradation is independent of its role in translation inhibition. [Abstract]

2025 Mar 27;44(4):115488. PMID: 40153437
Cell Rep

Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome. [Abstract]

2021 Oct 12;37(2):109806. PMID: 34644561
Cell Mol Life Sci

Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells. [Abstract]

2021 Sep;78(17-18):6337-6349. PMID: 34398253
PLoS Pathog

The NP protein of Newcastle disease virus dictates its oncolytic activity by regulating viral mRNA translation efficiency. [Abstract]

2024 Feb 20;20(2):e1012027. PMID: 38377149
Int J Mol Sci

eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma. [Abstract]

2023 Jan 20;24(3):2055. PMID: 36768380
Front Pharmacol

PINK1/Parkin-Mediated Mitophagy Regulation by Reactive Oxygen Species Alleviates Rocaglamide A-Induced Apoptosis in Pancreatic Cancer Cells. [Abstract]

2019 Sep 3:10:968. PMID: 31551778
Mol Cancer Res

HSF1-Mediated Control of Cellular Energy Metabolism and mTORC1 Activation Drive Acute T-Cell Lymphoblastic Leukemia Progression. [Abstract]

2020 Mar;18(3):463-476. PMID: 31744878
Cancers

Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells. [Abstract]

2020 Aug 4;12(8):2169. PMID: 32759815
iScience

Channeling macrophage polarization by rocaglates increases macrophage resistance to Mycobacterium tuberculosis. [Abstract]

2021 Jul 10;24(8):102845. PMID: 34381970
J Virol

Pseudorabies virus IE180 protein hijacks G3BPs into the nucleus to inhibit stress granule formation. [Abstract]

2025 Mar 27:e0208824. PMID: 40145738
Saudi Pharm J

Evaluation of the impact of Roclaglamide on MDA-MB-231 human breast adenocarcinoma cells by cell culture and molecular approaches. [Abstract]

2025 Jul 8;33(4):22. PMID: 40627085
Life Sci Alliance

Integrated stress response restricts macrophage necroptosis. [Abstract]

2021 Nov 11;5(1):e202101260. PMID: 34764207
Cancer Manag Res

Effective Inhibition of MYC-Amplified Group 3 Medulloblastoma Through Targeting EIF4A1. [Abstract]

2020 Dec 3;12:12473-12485. PMID: 33299354
Transl Cancer Res

Effect and mechanism of the miR-1284/EIF4A1 axis on the cGAS-STING pathway under radiotherapy. [Abstract]

2025 Apr 30;14(4):2483-2494. PMID: 40386253
bioRxiv

2025 Nov 18.
bioRxiv

Differentiation stage-specific use of cap-independent and cap-dependent translation initiation in hematopoiesis. [Abstract]

2025 Sep 25:2025.09.24.678136. PMID: 41040404
bioRxiv

Programmable translational inhibition by a molecular glue-oligonucleotide conjugate. [Abstract]

2025 Jul 16:2025.07.15.664547. PMID: 40791481
bioRxiv

2024 November 03.
University of California

2023 Sep.
bioRxiv

Cell state transition analysis identifies interventions that improve control of M. tuberculosis infection by susceptible macrophages. [Abstract]

2023 Feb 10:2023.02.09.527908. PMID: 36798271
bioRxiv

Systematic elucidation of genetic mechanisms underlying cholesterol uptake. [Abstract]

2023 Jan 10:2023.01.09.500804. PMID: 36711952
Patent

US20220362276A1.
Research Square Preprint

2021 Sep.
bioRxiv

Single-Molecule Dynamics of SARS-CoV-2 5' Cap Recognition by Human eIF4F. [Abstract]

2021 May 27:2021.05.26.445185. PMID: 34075378
The City University of New York

2021 Feb.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (197.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9780 mL

9.8900 mL

19.7800 mL

5 mM

0.3956 mL

1.9780 mL

3.9560 mL

10 mM

0.1978 mL

0.9890 mL

1.9780 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 7.5 mg/mL (14.84 mM); Clear solution

This protocol yields a clear solution of ≥ 7.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 7.5 mg/mL (14.84 mM); Clear solution

This protocol yields a clear solution of ≥ 7.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 5% DMSO 95% Saline

Solubility: ≥ 4.76 mg/mL (9.42 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

HepG2 and Huh-7 cells (1×10⁴/well) are seeded in 96-well plates in complete culture medium and incubated for 24 h. The cells are then exposed to 100 nM Rocaglamide and/or 100 ng/mL TRAIL for 24 h. The control cells are treated with DMSO at a concentration equal to that used for the drug-treated cells. The complete culture medium is then removed and MTT (200 μL, 0.5 mg/mL in 10% FBS-containing DMEM) is added to each well and the plate is incubated for 2 h at 37°C in a humidified incubator. The solution is then removed from the wells and 200 μL DMSO is added to each well prior to agitation. The absorbance at 570 nm is read using a microplate reader (Bio-Tek ELx800). The value for the vehicle-treated cells is considered to indicate 100% viability. Furthermore, a crystal violet assay is carried out. Briefly, the cells (1×10⁵/mL) are seeded in a 12 well plate for 12 h, and treated with TRAIL (0-100 ng/mL) and/or RocA(1-100 nM) for 12 h. The treated cells are washed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde for 15 min, and stained using crystal violet for a further 30 min^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
The Huh-7 cells (3×10⁶), suspended in 100 μL mix (equal volumes of DMEM and Matrigel), are implanted subcutaneously into the right flank of 10 female SCID mice (6-week-old) and then randomly divided into two equal groups, one of which received an intraperitoneal injection of Rocaglamide (2.5 mg/kg in 80 μL olive oil; n=5) and the other, used as a vehicle control, received olive oil alone (n=5). These treatments are performed once daily for 32 days and the tumor volumes and body weights of the animals are measured twice a week. The tumor volumes (mm³) are calculated using the following formula: Tumor volume=LS²/2, where L is the longest diameter and S is the shortest. At the end of the experiments, the mice are sacrificed and tumor samples are harvested, fixed in formalin and embedded in paraffin as tissue sections for immunohistochemical analysis.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (291 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Santagata S, et al. Tight coordination of protein translation and heat shock factor 1 activation supports the anabolic malignant state. Science. 2013 Jul 19; 341(6143): 1238303. [Content Brief]

[2]. Luan Z, et al. Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation. Mol Med Rep [Content Brief]

[3]. Baumann B, et al. Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. J Biol Chem. 2002 Nov 22;277(47):44791-800. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9780 mL	9.8900 mL	19.7800 mL	49.4501 mL
	5 mM	0.3956 mL	1.9780 mL	3.9560 mL	9.8900 mL
	10 mM	0.1978 mL	0.9890 mL	1.9780 mL	4.9450 mL
	15 mM	0.1319 mL	0.6593 mL	1.3187 mL	3.2967 mL
	20 mM	0.0989 mL	0.4945 mL	0.9890 mL	2.4725 mL
	25 mM	0.0791 mL	0.3956 mL	0.7912 mL	1.9780 mL
	30 mM	0.0659 mL	0.3297 mL	0.6593 mL	1.6483 mL
	40 mM	0.0495 mL	0.2473 mL	0.4945 mL	1.2363 mL
	50 mM	0.0396 mL	0.1978 mL	0.3956 mL	0.9890 mL
	60 mM	0.0330 mL	0.1648 mL	0.3297 mL	0.8242 mL
	80 mM	0.0247 mL	0.1236 mL	0.2473 mL	0.6181 mL
	100 mM	0.0198 mL	0.0989 mL	0.1978 mL	0.4945 mL

Keywords

Rocaglamide

31 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Rocaglamide

MCE Bioactive Compound Library

Natural Product Library Plus

Publications Citing Use of MedChemExpress (MCE) Rocaglamide

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle HSP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (31)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Rocaglamide

MCE Bioactive Compound Library

Natural Product Library Plus

Publications Citing Use of MedChemExpress (MCE) Rocaglamide

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle HSP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (31)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Rocaglamide Related Classifications

Art. -Nr.: HY-19356